(Q45347873)

13 December 2017

Selecting an antiretroviral regimen for human immunodeficiency virus postexposure prophylaxis in the occupational setting (English)

1 reference

13 December 2017

Darrell H S Tan

1

1 reference

13 December 2017

Blessing Goddey-Erikefe

2

1 reference

13 December 2017

Deborah Yoong

3

1 reference

13 December 2017

Mark Naccarato

4

1 reference

13 December 2017

Susan McIntyre

5

1 reference

13 December 2017

Roohi Qureshi

6

1 reference

13 December 2017

Kevin Gough

7

1 reference

13 December 2017

1 March 2014

1 reference

Infection Control and Hospital Epidemiology

13 December 2017

1 reference

13 December 2017

35

1 reference

13 December 2017

3

1 reference

13 December 2017

326-328

1 reference

Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials

13 December 2017

1 reference

Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis

21 January 2018

1 reference

Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.

21 January 2018

1 reference

Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1086/675297

1 reference

13 December 2017

1 reference